EDAP TMS Launches Ablatherm at Guy's Hospital, London

LYON, France, December 14  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP) announced today the adoption of the Ablatherm(R) HIFU System at Guy's & St. Thomas' NHS Foundation Hospital.

Declan Cahill, Consultant Urologist, Guy's & St. Thomas' NHS Foundation Hospital said, "Ablatherm(R) HIFU is the most exciting addition to the prostate cancer treatment armament. It fills significant gaps in the comprehensive management of prostate cancer allowing Guy's & St. Thomas' NHS Foundation Hospital to fit the treatment to the patient's quality of life as opposed to just the treatment."

Hugues de Bantel, Chief Executive Officer of EDAP-TMS, said, "This quality of life prostate cancer treatment with the Ablatherm(R) HIFU is available today at Guy's & St. Thomas' NHS Foundation Hospital. I am so pleased that a hospital that has pioneered so many breakthroughs has endorsed the technology of Ablatherm(R) HIFU by EDAP-TMS, who over many years developed Ablatherm(R) HIFU technology. This prostate cancer treatment is available at two other renowned NHS hospitals in the United Kingdom, Stepping Hill in Manchester and Royal Marsden in London. By the end of February 2006 this treatment will be available at more than 13 hospitals across the United Kingdom, mostly through our partner Mobile HIFU(TM). These 16 new Ablatherm(R) centres take the availability of Ablatherm(R) HIFU to more than 100 hospitals across Europe by early 2006."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by phone at [phone] or see the Company's Web site at: http://www.edap-tms.com/.

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.

  CONTACT:

  EDAP TMS S.A.
  Hugues de Bantel - Philippe Chauveau
  Blandine Confort
  [phone]

  Halliburton Investor Relations
  Matt Kreps - Geralyn DeBusk
  [phone]


DATASOURCE: EDAP TMS S.A.



CONTACT:  CONTACT: EDAP TMS S.A., Hugues de Bantel - Philippe Chauveau,

Blandine Confort, [phone]. Halliburton Investor Relations, Matt

Kreps - Geralyn DeBusk, [phone]

Copyright